ArticleMayo Clinic proceedings. Innovations, quality & outcomes2026
Real-World Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Nondiabetic Autosomal-Dominant Polycystic Kidney Disease: Effects on Progression to Dialysis in a TrinetX Cohort.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pseudo-Index Events Cannot be Configured on the TriNetX Platform.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- In Reply: Pseudo-Index Events cannot be Configured on the TriNetX Platform.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between sodium-glucose cotransporter-2 inhibitor (SGLT2i) use and the risk of progression to chronic dialysis in nondiabetic adults with autosomal-dominant polycystic kidney disease (ADPKD). Patients and Methods: This retrospective cohort study used the TriNetX Global Collaborative Network to identify nondiabetic adults newly diagnosed with ADPKD since 2018. We performed 1:1 propensity score matching to balance 21 baseline covariates between SGLT2i users and controls. Secondary analyses compared tolvaptan users with matched controls and performed a direct comparison between SGLT2i and tolvaptan. The primary outcome was chronic dialysis initiation, analyzed via Kaplan-Meier and Cox proportional hazards models. Results: After matching, 187 patients were included in each cohort. Dialysis initiation occurred in 19 (10.16%) SGLT2i users vs 43 (22.99%) controls ( Conclusion: Sodium-glucose cotransporter-2 inhibitor therapy was associated with a substantially reduced risk of progressing to dialysis in this real-world nondiabetic ADPKD cohort. Although these findings are promising, prospective randomized trials are essential to confirm these results and to evaluate the longitudinal impact of SGLT2i on cyst growth and total kidney volume.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.